sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a disclosure under Form 8.3 of the Irish Takeover Panel Act regarding its stake in Avadel Pharmaceuticals plc. As of November 14, 2025, Vanguard controls 5,527,141 ordinary shares, which equates to 5.67% of Avadel's relevant securities.
The disclosure does not involve any parties other than Avadel Pharmaceuticals, and there were no dealings in cash-settled or stock-settled derivative transactions. A small purchase of 1,927 ordinary shares was made at a price of 23.56 USD per unit.
No agreements, indemnities, or options related to these securities have been disclosed. The filing confirms a straightforward shareholder position without additional financial instruments or arrangements affecting Avadel's shares.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.